Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Compass Therapeutics, Inc. CMPX

Healthcare  —  Biotechnology
1.13 (0.01) (0.88%) as of 25 Sep
Market cap
$205.3M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Compass Therapeutics, Inc. (CMPX) Business Profile

Updated before January 2025

Company Overview

Compass Therapeutics, Inc. (CMPX) is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation antibody-based therapeutics for the treatment of cancer and autoimmune diseases. Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics leverages its proprietary StitchMabs™ platform to design and develop novel antibody therapeutics. The company was co-founded by Thomas Schuetz, MD, PhD, who also serves as the Chief Executive Officer. Under his leadership, Compass Therapeutics has grown into a prominent player in the biotechnology sector, with a focus on advancing innovative therapies to address unmet medical needs.

The company’s leadership team includes experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and clinical research. This includes key executives such as the Chief Scientific Officer and Chief Financial Officer, who bring a wealth of expertise to Compass Therapeutics’ strategic and operational initiatives.

Core Business Segments

Compass Therapeutics operates primarily in the biotechnology and pharmaceutical sectors, with a focus on developing antibody-based therapeutics. The company’s core business segments include:

Oncology Therapeutics

Compass Therapeutics is heavily invested in the development of therapies targeting various forms of cancer. Its lead product candidate, CTX-009, is a bispecific antibody designed to inhibit both DLL4 and VEGF pathways, which are critical in tumor growth and angiogenesis. CTX-009 is currently undergoing clinical trials and has shown promising results in preclinical studies.

Autoimmune Disease Therapies

In addition to oncology, Compass Therapeutics is exploring treatments for autoimmune diseases. The company’s pipeline includes antibody candidates that target specific immune pathways to modulate the immune system and reduce inflammation. These therapies aim to provide relief for patients suffering from chronic autoimmune conditions.

Proprietary Platforms

Compass Therapeutics has developed proprietary platforms, such as StitchMabs™, which enable the design and engineering of bispecific and multifunctional antibodies. These platforms are integral to the company’s ability to create innovative therapeutics that address complex diseases.

Business Model

Compass Therapeutics operates on a research-driven business model that integrates cutting-edge technology, clinical development, and strategic partnerships. The company generates revenue through licensing agreements, collaborations with other biotechnology firms, and potential future product sales. By focusing on high-value therapeutic areas such as oncology and autoimmune diseases, Compass Therapeutics aims to maximize its market impact and financial returns.

The company’s approach involves:

  • Research and Development (R&D): Investing heavily in preclinical and clinical research to advance its pipeline of antibody-based therapeutics.
  • Strategic Partnerships: Collaborating with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development and commercialization.
  • Intellectual Property: Protecting its innovations through a robust portfolio of patents and proprietary technologies.

Strategic Direction

Compass Therapeutics is committed to expanding its pipeline of antibody-based therapeutics and advancing its clinical programs. The company’s strategic priorities include:

  • Pipeline Expansion: Developing additional bispecific and multifunctional antibodies to address a broader range of diseases.
  • Clinical Advancements: Progressing its lead candidates, such as CTX-009, through clinical trials and regulatory approvals.
  • Global Reach: Establishing a presence in international markets to increase access to its therapies.
  • Sustainability Goals: Incorporating environmentally sustainable practices into its operations and supply chain.

Competitive Landscape

Compass Therapeutics operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Amgen Inc.: A leader in oncology and autoimmune disease therapies.
  • Regeneron Pharmaceuticals: Known for its innovative antibody-based treatments.
  • Genentech (a member of the Roche Group): A pioneer in antibody therapeutics.
  • Smaller Biotech Firms: Companies such as MacroGenics and Xencor, which also focus on bispecific antibodies.

Compass Therapeutics differentiates itself through its proprietary platforms and focus on next-generation antibody therapeutics.

Risk Factors

Like any biotechnology company, Compass Therapeutics faces several risks, including:

  • Regulatory Challenges: The lengthy and uncertain process of obtaining regulatory approvals for new drugs.
  • Market Dependence: Reliance on the success of its lead product candidates, such as CTX-009.
  • Supply Chain Disruptions: Potential delays in the manufacturing and distribution of clinical trial materials.
  • Competitive Pressure: Intense competition from larger pharmaceutical companies and other biotech firms.
  • Financial Risks: The high costs associated with R&D and clinical trials, coupled with the uncertainty of future revenue streams.

Recent Developments

Compass Therapeutics has made significant progress in advancing its clinical pipeline. Recent developments include:

  • Clinical Trials: Positive interim results from Phase 1/2 clinical trials of CTX-009, demonstrating its potential efficacy and safety in treating certain cancers.
  • Partnerships: New collaborations with academic institutions to explore additional therapeutic applications for its antibody platforms.
  • Corporate Strategies: Expansion of its R&D facilities to support the development of next-generation therapeutics.

Global developments, such as the COVID-19 pandemic, have also impacted Compass Therapeutics, leading to adjustments in clinical trial timelines and operational strategies.

Investment Considerations

Investors considering Compass Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: A robust portfolio of antibody-based therapeutics targeting high-value markets.
  • Proprietary Technology: Unique platforms like StitchMabs™ that provide a competitive edge.
  • Experienced Leadership: A management team with deep expertise in biotechnology and pharmaceuticals.

Risks

  • Clinical and Regulatory Uncertainty: The inherent risks associated with drug development and approval.
  • Financial Volatility: Dependence on external funding and potential delays in revenue generation.
  • Market Competition: Intense competition from established players and emerging biotech firms.

Conclusion

Compass Therapeutics, Inc. is a promising biotechnology company with a strong focus on developing next-generation antibody-based therapeutics. While the company faces challenges typical of the biotech sector, its innovative pipeline, proprietary platforms, and experienced leadership position it well for future growth. As Compass Therapeutics advances its clinical programs and expands its global reach, it has the potential to make a significant impact in the fields of oncology and autoimmune disease treatment.